April A N Rose Selected Research

glembatumumab vedotin

1/2022	HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
11/2017	Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.
12/2016	MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.
11/2014	Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
4/2010	Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

April A N Rose Research Topics

Disease

16	Neoplasms (Cancer) 01/2022 - 09/2006
8	Breast Neoplasms (Breast Cancer) 01/2022 - 09/2006
7	Melanoma (Melanoma, Malignant) 01/2022 - 08/2010
7	Neoplasm Metastasis (Metastasis) 11/2017 - 09/2006
2	Triple Negative Breast Neoplasms 01/2022 - 04/2010
1	Thrombotic Microangiopathies 05/2022
1	Hypertension (High Blood Pressure) 05/2022
1	Kaposi Sarcoma (Kaposi's Sarcoma) 05/2022
1	Proteinuria 05/2022
1	Mumps 07/2021
1	Uveal melanoma 07/2021
1	Disease Progression 01/2021
1	COVID-19 01/2021
1	Colorectal Neoplasms (Colorectal Cancer) 01/2018
1	Inborn Genetic Diseases (Disease, Hereditary) 08/2010
1	Carcinoma (Carcinomatosis) 08/2010
1	Bone Resorption 09/2006

Drug/Important Bio-Agent (IBA)

5	glembatumumab vedotinIBA 01/2022 - 04/2010
5	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2006
4	Glycoproteins (Glycoprotein)IBA 01/2022 - 04/2010
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 12/2016
4	Immunoconjugates (Immunoconjugate)IBA 11/2017 - 04/2010
3	Immune Checkpoint InhibitorsIBA 07/2021 - 01/2021
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2018
1	CreatinineIBA 05/2022
1	liposomal doxorubicin (Doxil)FDA Link 05/2022
1	Pharmaceutical PreparationsIBA 05/2022
1	Programmed Cell Death 1 ReceptorIBA 01/2021
1	Biological ProductsIBA 01/2021
1	Phosphotransferases (Kinase)IBA 12/2018
1	Therapeutic UsesIBA 01/2018
1	Protein Kinases (Protein Kinase)IBA 01/2018
1	Monoclonal AntibodiesIBA 01/2018
1	Immunologic Factors (Immunomodulators)IBA 11/2017
1	Differentiation AntigensIBA 12/2016
1	Capecitabine (Xeloda)FDA Link 11/2014
1	taxaneIBA 11/2014
1	AnthracyclinesIBA 11/2014
1	Vitamin D FDA LinkGeneric 10/2013
1	Calcitriol (Calcijex)FDA LinkGeneric 10/2013
1	IgA receptor (protein B)IBA 08/2010
1	Protein Isoforms (Isoforms)IBA 08/2010
1	RNA IsoformsIBA 08/2010
1	Messenger RNA (mRNA)IBA 08/2010
1	GalactosidesIBA 06/2010
1	Galectins (Galectin)IBA 06/2010
1	Carrier Proteins (Binding Protein)IBA 06/2010
1	Indicators and Reagents (Reagents)IBA 04/2010
1	Diphosphonates (Bisphosphonates)IBA 01/2010
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2010
1	src-Family KinasesIBA 01/2010
1	Cathepsin KIBA 01/2010
1	Estrogen ReceptorsIBA 10/2007
1	Cell Surface ReceptorsIBA 09/2006

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2010
1	Kidney Transplantation 05/2022
1	Aftercare (After-Treatment) 05/2022
1	Investigational Therapies (Experimental Therapy) 01/2022
1	Critical Care (Surgical Intensive Care) 01/2021
1	Subcutaneous Injections 12/2016
1	Drug Therapy (Chemotherapy) 11/2014
1	Injections 09/2006